<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01745549</url>
  </required_header>
  <id_info>
    <org_study_id>AGO01</org_study_id>
    <nct_id>NCT01745549</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Satisfaction of the New Pen Needle 33 Gauge x 4 mm.</brief_title>
  <acronym>AGO01</acronym>
  <official_title>Efficacy, Safety and Satisfaction of the New Pen Needle 33G x 4 mm 33G x 4 mm: Cross-over Randomized Controlled Clinical Trial. Studio AGO 01</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Consorzio Mario Negri Sud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Artsana SpA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Consorzio Mario Negri Sud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      During the last years, even more little needles are used for the injection of sub cutaneous
      insulin, for the diabetes therapy.

      The aim of this study is to evaluate the non inferiority of a new needle, smaller than
      another needle, in terms of hematic levels od fructosamine, an indicator of glycemic control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hematic fructosamine levels</measure>
    <time_frame>Change from baseline in fructosamine levels after 3 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean amplitude of glucose excursions (MAGE)</measure>
    <time_frame>Change from baseline in MAGE after 3 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain</measure>
    <time_frame>questionnaire at the end of the treatments (at 6 weeks)</time_frame>
    <description>visual analogic scale (VAS) 1-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>leakage at the site injection</measure>
    <time_frame>number of episodes of leakage during the treatment (3 weeks)</time_frame>
    <description>visual scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypoglycemia</measure>
    <time_frame>number of episodes of hypoglycemia during the treatment (3 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin dosage</measure>
    <time_frame>Change from baseline in insulin dosage after 3 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient's weight</measure>
    <time_frame>Change from baseline in weight after 3 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient's satisfaction</measure>
    <time_frame>questionnaire at the end of the treatments (at 6 weeks)</time_frame>
    <description>VAS scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>needle 4 mm gauge 33</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Needle for insulin pen, 4 mm long and with a diameter of 33 gauge (the smaller needle)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>needle 4 mm gauge 32</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Needle for insulin pen, 4 mm long and with a diameter of 32 gauge</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Needle for insulin pen, 4 mm long and with a diameter of 33 gauge</intervention_name>
    <arm_group_label>needle 4 mm gauge 33</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Needle for insulin pen, 4 mm long and with a diameter of 32 gauge</intervention_name>
    <arm_group_label>needle 4 mm gauge 32</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with type 1 or type 2 diabetes

          -  both males and females

          -  age &gt;=18 anni

          -  insulin treatment from at least 6 months

          -  signed informed consent

        Exclusion Criteria:

          -  pregnancy

          -  incapacity for filling in the questionnaires

          -  every illness or condition that, according to the investigator, could interfere with
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Nicolucci, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Consorzio Mario Negri Sud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UO Malattie Metaboliche e Diabetologia - Ospedale di Treviglio-Caravaggio</name>
      <address>
        <city>Treviglio</city>
        <state>BG</state>
        <zip>24047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Diabetologia per Trattamento e Educazione dei Diabetici - Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.S. Diabetologia e Malattie Metaboliche - PO Cant√π - Mariano Comense</name>
      <address>
        <city>Mariano Comense</city>
        <state>CO</state>
        <zip>22066</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa Dietologia-Diabetologia Malattie Metaboliche - Ospedale Pertini</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2012</study_first_submitted>
  <study_first_submitted_qc>December 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2012</study_first_posted>
  <last_update_submitted>March 17, 2014</last_update_submitted>
  <last_update_submitted_qc>March 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Consorzio Mario Negri Sud</investigator_affiliation>
    <investigator_full_name>Antonio Nicolucci</investigator_full_name>
    <investigator_title>Dr Antonio Nicolucci, MD</investigator_title>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>insulin therapy</keyword>
  <keyword>needle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

